Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605? under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Brilliant Violet 605? excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605? is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.⁴ The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
4. Li B, et al. 2005. Immunology 116:487.
5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed

Product Citations

1. Stegmann K, et al. 2016. Sci Rep. 6: 26157. PubMed
2. Carre C, et al. 2021. iScience. 24:102970. PubMed
3. Marquardt I, et al. 2022. Front Microbiol. 12:752549. PubMed
4. Tan AT, et al. 2021. J Clin Invest. 131:. PubMed
5. Swadling L, et al. 2020. Cell Rep. 30:687. PubMed
6. Rodriguez-García A, et al. 2020. Mol Ther. 28:548. PubMed
7. Jing Li et al. 2018. Immunity. 48(4):773-786 . PubMed
8. Dyring-Andersen B, et al. 2020. Nat Commun. 4.338194444. PubMed
9. Huang B, et al. 2020. Cell. 179(5):1160-1176.e24.. PubMed
10. Cao W, et al. 2017. Immunity. 47:1182. PubMed
11. Richert-Spuhler LE, et al. 2021. Cell Reports Medicine. 2(6):100322. PubMed
12. Kalimuddin S, et al. 2021. Med. 2(6):682-688.e4. PubMed
13. Watanabe K, et al. 2018. JCI Insight. 3. PubMed
14. Kuo HH, et al. 2018. Immunity. 48:1183. PubMed
15. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
16. Gullà A, et al. 2021. Cancer Discov. . PubMed
17. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
18. Martín–Gayo E, et al. 2020. Cell Rep. 30:984. PubMed
19. Mengrelis K, et al. 2021. Pediatr Transplant. 25:e13930. PubMed
20. Zimmerman KA, et al. 2019. J Am Soc Nephrol. 30:767. PubMed
21. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
22. Johnson JK, et al. 2022. Methods Mol Biol. 2470:641. PubMed
23. Khoo NKH, et al. 2022. Med (N Y). 3:104. PubMed
24. Kim MY, et al. 2018. Cell. 173:1439. PubMed
25. Xu C, et al. 2020. Methods Mol Biol. 2108:159. PubMed
26. Day C, et al. 2017. J Immunol. 10.4049/jimmunol.1700558. PubMed
27. Leng T, et al. 2019. Cell Rep. 28:3077. PubMed
28. Shuwa HA, et al. 2021. Med. 2(6):720-735.e4. PubMed
29. Giudice V, et al. 2017. Cytometry A. 10.1002/cyto.a.23162. PubMed
30. Baxter AE, et al. 2017. Nat Protoc. 12:2029. PubMed
31. Gullà A, et al. 2021. Cancer Discov. 2:468. PubMed
32. Panigrahi S, et al. 2020. Eur J Immunol. 50:2055. PubMed
33. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
34. Zimmerman KA, et al. 2019. Physiol Rep. 7:e13951. PubMed

RRID

AB_11126166 (BioLegend Cat. No. 317321) AB_2561911 (BioLegend Cat. No. 317322)